Rheumatoid Arthritis Clinical Trials in Philadelphia

Showing 2361-2380 of 3,895 trials

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

NCT00503243

The aim of this study was to investigate the safety and efficacy of SPD476 2.4 g/day given twice daily (\[BID\] ie 1.2 g/day BID) and SPD476 4.8g/day given QD compared to placebo in subjects with acute, mild to moderate ulcerative colitis.

Colitis, Ulcerative

Shire280 participantsStarted Sep 2003

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 2< 1 mile

A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

NCT02842242

The purpose of this phase 2 open-label pilot study is to evaluate the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of MYK-461 in subjects with symptomatic HCM and LVOT obstruction aged 18-70 years.

Cardiomyopathy, Hypertrophic ObstructiveLeft Ventricular Outflow Tract Obstruction

MyoKardia, Inc.21 participantsStarted Aug 2016

Scottsdale, Arizona, United States • New Haven, Connecticut, United States • Boston, Massachusetts, United States +4 more locations

COMPLETEDPhase 3< 1 mile

Phase 3 Study of Dexpramipexole in ALS

NCT01281189

The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).

Amyotrophic Lateral Sclerosis

Knopp Biosciences942 participantsStarted Mar 2011

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Fresno, California, United States +79 more locations

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Phase 3 Study of Dexpramipexole in ALS

Rheumatoid Arthritis Trials in Other Cities

Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches

Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients

DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis

Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)

Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®

A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

Bupivacaine Effectiveness and Safety in SABER® Trial

A Randomized Control Trial of Hip Dislocation Techniques for Pediatric Patients With Cerebral Palsy

GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

Other Conditions in Philadelphia